STOCK TITAN

Rigel Pharmaceuticals - RIGL STOCK NEWS

Welcome to our dedicated news page for Rigel Pharmaceuticals (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rigel Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rigel Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
-
Rhea-AI Summary
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) will report its Q2 2023 financial results on August 1, 2023, after market close. A live conference call and webcast will follow the announcement to discuss the financial results and provide a business update. Participants can access the call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The webcast will be available on the company's website and can be replayed for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.31%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.09%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
conferences
-
Rhea-AI Summary
Rigel Pharmaceuticals reports Q1 2023 total revenue of $26.1 million, with TAVALISSE net product sales of $22.3 million and REZLIDHIA net product sales of $1.5 million. The company sees a 47% increase in net product sales compared to Q1 2022. Rigel is focused on driving growth in both TAVALISSE and REZLIDHIA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rigel Pharmaceuticals

Nasdaq:RIGL

RIGL Rankings

RIGL Stock Data

210.49M
146.96M
2.11%
61.38%
2.86%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
South San Francisco

About RIGL

rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.